Twenty-four Month Outcomes in the Collaborative Ocular Tuberculosis Study (COTS)-1: Defining the "Cure" in Ocular Tuberculosis
Yazar
Invernizzi, Alessandro
Singh, Ramandeep
Sharma, Aman
Sharma, Kusum
Zierhut, Manfred
Kon, Onn Min
Cunningham, Emmett T.
Kempen, John H.
Agarwal, Aniruddha
Agrawal, Rupesh
Raje, Dhananjay
Testi, Ilaria
Mahajan, Sarakshi
Gunasekeran, Dinesh Visva
Aggarwal, Kanika
Murthy, Somasheila
Westcott, Mark
Chee, Soon-Phaik
Mccluskey, Peter
Ho, Su Ling
Teoh, Stephen
Cimino, Luca
Pavesio, Carlos
Quan Dong Nguyen, Quan Dong Nguyen
Gupta, Vishali
Biswas, Jyotirmay
Narain, Shishir
Agarwal, Manisha
Mahendradas, Padmamalini
Khairallah, Moncef
Jones, Nicholas
Tugal-Tutkun, Ilknur
Babu, Kalpana
Basu, Soumayava
Carreno, Ester
Lee, Richard
Al-Dhibi, Hassan
Bodaghi, Bahram
Goldstein, Debra A.
Herbort, Carl P.
Barisani-Asenbauer, Talin
Gonzalez-Lopez, Julio J.
Androudi, Sofia
Bansal, Reema
Moharana, Bruttendu
Degli Esposti, Simona
Tasiopoulou, Anastasia
Nadarajah, Sengal
Agarwal, Mamta
Abraham, Sharanya
Vala, Ruchi
Üst veri
Tüm öğe kaydını gösterÖzet
Purpose To report the clinical findings, anatomical features, and treatment outcomes in subjects with ocular tuberculosis (OTB) at 24 months in the Collaborative Ocular Tuberculosis Study (COTS)-1. Methods Of the 945 subjects included in COTS-1, those who completed a 24-month follow-up after completion of treatment were included. The main outcome measure was a number of patients with treatment failure (TF). Results 228 subjects (120 males; mean age of 42.82 +/- 14.73 years) were included. Most common phenotype of uveitis was posterior (n= 81; 35.53%), and panuveitis (n= 76; 33.33%). Fifty-two patients (22.81%) had TF. On univariable analysis, odds of high TF was observed with bilaterality (OR: 3.46,p= .003), vitreous haze (OR: 2.14,p= .018), and use of immunosuppressive therapies (OR: 5.45,p= .003). However, only bilaterality was significant in the multiple regression model (OR: 2.84;p= .02). Conclusions Majority of subjects (>75%) achieved cure in the COTS-1 at 24-month follow-up. The concept of "cure" may be a valuable clinical endpoint in trials for OTB.
Koleksiyonlar
- Makale [92796]